ClinicalTrials.gg
Active, not recruitingNCT06537414B-UNITEDUpdated Nov 6, 2026

A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

A Phase 2 interventional study of Daplusiran/Tomligisiran Dose Level 1 and Daplusiran/Tomligisiran Dose Level 2 in Chronic Hepatitis B Virus Infection and Hepatitis B, sponsored by GlaxoSmithKline. Active, not recruiting at 80 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

How we know

Updated Nov 6, 20264 sites added4 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
283
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Hepatitis B, Chronic by GlaxoSmithKline — 1 open to participants now, 2 under way, none of them phase 3. Hepatitis B, Chronic · GlaxoSmithKline.

Enrollment
9th of 28
283 · median 163
Started
2024
the only one that year
Phase 2
5 of 30
none open now
Registered
29th of 30
by date

Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, this one is the 9th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2024, is one of 5 in phase 2, and was the 29th registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline is open now. Recruiting first, the newest first:

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, or all of them as a file.
02

Study summary

The study is intended to evaluate the efficacy and safety of 2 different doses of DAP/TOM followed by bepirovirsen in participants living with CHB on standard of care nucleos(t)ide analogue (NA) therapy. The study also aims to identify an optimal dose of DAP/TOM for sequenced therapy with bepirovirsen for further clinical development and to assess the contribution of DAP/TOM to the sequential regimen. The study will also include an optional long-term follow-up (LTFU) extension stage for eligible participants.

03

Conditions studied

  • Chronic Hepatitis B Virus Infection
  • Hepatitis B

Keywords

  • Bepirovirsen
  • B-UNITED
  • Daplusiran/Tomligisiran
  • Hepatitis B
  • Nucleos(t)ide analogue
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: At least 18 years of age at the time of signing the
  • Documented chronic infection greater than or equal to (>=) 6 months prior to Screening AND currently receiving stable NA therapy defined as receiving an NA regimen form at least 6 months prior to Screening and with no planned changes to their stable regimen over the duration of the study.
  • Plasma or serum HBsAg concentration greater than (>) 100 international units per milliliter (IU/mL)
  • Plasma or serum HBV DNA concentration must be adequately suppressed, defined as plasma or serum HBV DNA less than (\<) 90 IU/mL
  • less than or equal to (\<=) 2* (ULN)
  • Participants who are willing and able to cease their NA treatment in accordance with the protocol.
  • Male and Female

Exclusion criteria

Exclusion Criteria:

  • abnormalities, aside from chronic infection in medical history (e.g., moderate-severe liver disease other than chronic HBV, acute coronary syndrome within 6 months of screening, major surgery within 3 months of screening, significant/unstable cardiac disease, uncontrolled diabetes, bleeding diathesis coagulopathy) or clinically significant physical examination findings.
  • Coinfection with (cured \<12 months at the time of screening), or hepatitis D virus
  • History of or suspected liver cirrhosis and/or evidence of cirrhosis.
  • Diagnosed or suspected hepatocellular carcinoma.
  • History of within the past 5 years with the exception of specific cancers that are cured by surgical resection (example, skin cancer). Participants under evaluation for possible malignancy are not eligible.
  • History of vasculitis or presence of symptoms and signs of potential vasculitis (e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause), current or history of an condition or history/presence of other diseases that may be associated with vasculitis condition (example, systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, mononeuritis multiplex).
  • History of extrahepatic disorders possibly related to HBV immune conditions (example, nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa, cryoglobulinemia, uncontrolled hypertension).
  • History of alcohol or drug abuse/dependence:
  • Currently taking, or took within 3 months of screening, any drugs (example, prednisone), other than a short course of therapy (\<=2 weeks) or topical/inhaled use.
  • Participants, to whom immunosuppressive treatment (including therapeutic doses of steroids) is , should not be considered for enrollment in the study.
  • Currently taking, or has taken within 6 months of Screening, any interferon-containing therapy.
  • Participants requiring anti-coagulation therapies (example, warfarin, Factor Xa inhibitors) or anti- agents (like clopidogrel or aspirin) unless treatment can safely be discontinued throughout duration of medicinal product (IMP) treatment, by the discretion of the investigator. Occasional use is permitted.
  • Prior hepatitis B treatment with bepirovirsen, DAP/TOM, or another oligonucleotide or small interfering RNA (siRNA).
  • Prior non-hepatitis B treatment with an oligonucleotide or siRNA within 12 months prior to the first dosing day.
  • Fridericia's correction formula (QTcF) >=450 millisecond (msec) (if single [ECG] at screening shows QTcF >=450 msec, a mean of triplicate measurements should be used to confirm that participant meets exclusion criterion).
  • History of/sensitivity to bepirovirsen, DAP/TOM or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation
  • Participants who do not wish to discontinue taking NA therapy for their chronic HBV infection.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
283 participants (actual)

Study arms

  • Experimental
    Treatment Arm 1A: DAP/TOM + Bepirovirsen

    Participants with high Hepatitis B surface antigen (HBsAg) level will receive dose level 1 of DAP/TOM in Treatment Stage 1. After DAP/TOM Treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment.

    Drug: Daplusiran/Tomligisiran Dose Level 1 · Drug: Bepirovirsen

  • Experimental
    Treatment Arm 1B: DAP/TOM + Bepirovirsen

    Participants with high HBsAg level will receive dose level 2 of DAP/TOM in Treatment Stage 1. After DAP/TOM treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment.

    Drug: Daplusiran/Tomligisiran Dose Level 2 · Drug: Bepirovirsen

  • Experimental
    Treatment Arm 2A: DAP/TOM + Bepirovirsen

    Participants with low HBsAg level will receive dose level 1 of DAP/TOM in Treatment Stage 1. After DAP/TOM treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment.

    Drug: Daplusiran/Tomligisiran Dose Level 1 · Drug: Bepirovirsen

  • Experimental
    Treatment Arm 2B: DAP/TOM + Bepirovirsen

    Participants with low HBsAg level will receive dose level 2 of DAP/TOM in Treatment Stage 1. After DAP/TOM treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment.

    Drug: Daplusiran/Tomligisiran Dose Level 2 · Drug: Bepirovirsen

  • Experimental
    Treatment Arm 2C: Placebo + Bepirovirsen

    Participants with low HBsAg level will receive Placebo in Treatment Stage 1. After Placebo treatment, eligible participants will receive bepirovirsen in Treatment Stage 2. All participants will continue background NA treatment throughout these treatment stages. After bepirovirsen Treatment Stage, participants will be observed during the NA Only Stage, while maintaining background NA treatment. Eligible participants will then discontinue background NA treatment.

    Drug: Bepirovirsen · Drug: Placebo

Interventions

  • DrugDaplusiran/Tomligisiran Dose Level 1

    Daplusiran/Tomligisiran dose level 1 will be administered

  • DrugDaplusiran/Tomligisiran Dose Level 2

    Daplusiran/Tomligisiran dose level 2 will be administered

  • Bepirovirsen will be administered

  • DrugPlacebo

    Placebo will be administered

06

What researchers measure

Primary outcomes

  1. Number of participants achieving functional cure

    The functional cure for HBV is defined as sustained suppression (24 weeks or longer) of HBV deoxyribonucleic acid (DNA) \<lower limit of quantification (LLOQ) and HBsAg not detected with or without HBsAb after a finite duration of therapy and off all HBV treatment. The number of participants achieving functional cure after discontinuation of all chronic HBV treatments (DAP/TOM, bepirovirsen, and NA treatment) will be reported.

    Time frame: Up to 100 Weeks

Secondary outcomes

  1. Number of participants achieving functional cure with high Baseline HBsAg level

    The functional cure for HBV is defined as sustained suppression (24 weeks or longer) of HBV DNA \<LLOQ and HBsAg not detected with or without HBsAb after a finite duration of therapy and off all HBV treatment. The number of participants achieving functional cure with high Baseline HBsAg level after discontinuation of all chronic HBV treatments (DAP/TOM, bepirovirsen, and NA treatment) will be reported.

    Time frame: Up to 100 Weeks

  2. Number of participants achieving functional cure with low Baseline HBsAg level

    The functional cure for HBV is defined as sustained suppression (24 weeks or longer) of HBV DNA \<LLOQ and HBsAg not detected with or without HBsAb after a finite duration of therapy and off all HBV treatment. The number of participants achieving functional cure with low Baseline HBsAg level after discontinuation of all chronic HBV treatments (DAP/TOM, bepirovirsen, and NA treatment) will be reported.

    Time frame: Up to 100 Weeks

  3. Number of participants achieving functional cure with low Baseline HBsAg level compared against placebo + bepirovirsen arm

    The functional cure for HBV is defined as sustained suppression (24 weeks or longer) of HBV DNA \<LLOQ and HBsAg not detected with or without HBsAb after a finite duration of therapy and off all HBV treatment. The number of participants achieving functional cure with low Baseline HBsAg level after discontinuation of all chronic HBV treatments (DAP/TOM, bepirovirsen, and NA treatment) compared against placebo + bepirovirsen arm will be reported.

    Time frame: Up to 100 Weeks

  4. Number of participants with undetected HBsAg and HBV DNA <LLOQ

    The number of participants with undetected HBsAg and HBV DNA \<LLOQ at the end of bepirovirsen treatment will be reported.

    Time frame: Up to 48 Weeks

07

Study locations

80 sites
  • GSK Investigational Site
    San Francisco, California 94115, United States
  • GSK Investigational Site
    San Jose, California 95116, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55415, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • GSK Investigational Site
    Westmead, New South Wales 2145, Australia
  • GSK Investigational Site
    Fitzroy, Victoria 3065, Australia
  • GSK Investigational Site
    Ghent, Oost-Vlaanderen 9000, Belgium
  • GSK Investigational Site
    Brussels, 1000, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Aracaju, 49060-010, Brazil
  • GSK Investigational Site
    Curitiba, 80810-050, Brazil
  • GSK Investigational Site
    Manaus, 69040-000, Brazil
  • GSK Investigational Site
    São Paulo, 05403-000, Brazil
  • GSK Investigational Site
    Calgary, Alberta T2N 4Z6, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2C4, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Beijing, 100050, China
  • GSK Investigational Site
    Chengdu, 610072, China
  • GSK Investigational Site
    Guangzhou, 510630, China
  • GSK Investigational Site
    Shanghai, 200040, China
  • GSK Investigational Site
    Clichy, 92118, France
  • GSK Investigational Site
    Créteil, 94010, France
  • GSK Investigational Site
    Limoges, 87042, France
  • GSK Investigational Site
    Lyon, 69004, France
  • GSK Investigational Site
    Marseille, 13008, France
  • GSK Investigational Site
    Hanover, Lower Saxony 30625, Germany
  • GSK Investigational Site
    Berlin, 10439, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Münster, 48149, Germany
  • GSK Investigational Site
    Athens, 10676, Greece
  • GSK Investigational Site
    Athens, 11527, Greece
  • GSK Investigational Site
    Pokfulam, Hong Kong
  • GSK Investigational Site
    Shatin, Hong Kong
  • GSK Investigational Site
    Bergamo, 24127, Italy
  • GSK Investigational Site
    Florence, 50134, Italy
  • GSK Investigational Site
    Milan, Italy
  • GSK Investigational Site
    Naples, 80131, Italy
  • GSK Investigational Site
    Padova, 35131, Italy
  • GSK Investigational Site
    Pisa, 56124, Italy
  • GSK Investigational Site
    Roma, 00161, Italy
  • GSK Investigational Site
    Chiba, 270-1694, Japan
  • GSK Investigational Site
    Hokkaido, 006-8555, Japan
  • GSK Investigational Site
    Hokkaido, 053-8506, Japan
  • GSK Investigational Site
    Hyōgo, 660-8550, Japan
  • GSK Investigational Site
    Kagawa, 760-8557, Japan
  • GSK Investigational Site
    Kagawa, 761-0793, Japan
  • GSK Investigational Site
    Kumamoto, 860-8556, Japan
  • GSK Investigational Site
    Kumamoto, 862-8655, Japan
  • GSK Investigational Site
    Osaka, 540-0006, Japan
  • GSK Investigational Site
    Osaka, 565-0871, Japan
  • GSK Investigational Site
    Tokyo, 180-8610, Japan
  • GSK Investigational Site
    Yamanashi, 409-3898, Japan
  • GSK Investigational Site
    Auckland, 1023, New Zealand
  • GSK Investigational Site
    Auckland, 2025, New Zealand
  • GSK Investigational Site
    Singapore, 119074, Singapore
  • GSK Investigational Site
    Singapore, 169608, Singapore
  • GSK Investigational Site
    Ekurhuleni, 1459, South Africa
  • GSK Investigational Site
    Johannesburg, 2193, South Africa
  • GSK Investigational Site
    Ansan, 15355, South Korea
  • GSK Investigational Site
    Busan, 47392, South Korea
  • GSK Investigational Site
    Pusan, 49241, South Korea
  • GSK Investigational Site
    Seoul, 07061, South Korea
  • GSK Investigational Site
    Seoul, 138-736, South Korea
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain
  • GSK Investigational Site
    León, 24080, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Salamanca, 37007, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain
  • GSK Investigational Site
    Kaohsiung City, 807, Taiwan
  • GSK Investigational Site
    Kaohsiung City, 824, Taiwan
  • GSK Investigational Site
    Taichung, 404, Taiwan
  • GSK Investigational Site
    Tau-Yuan, 333, Taiwan
  • GSK Investigational Site
    London, E1 8PR, United Kingdom
  • GSK Investigational Site
    London, SE5 9RS, United Kingdom
  • GSK Investigational Site
    London, SW17 0QT, United Kingdom
  • GSK Investigational Site
    Middlesbrough, TS4 3BW, United Kingdom
08

References and documents

Publications

  • Hong J, Rajwanshi VK. Antisense oligonucleotides as drugs with both direct and indirect antiviral actions. Antiviral Res. 2025 Aug;240:106219. doi: 10.1016/j.antiviral.2025.106219. Epub 2025 Jun 23. PubMed 40562220 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for May 2027, 30 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 30 months is above that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2024
First posted
Aug 5, 2024
StartActual
Nov 11, 2024
Primary completionEst.
May 31, 2027
CompletionEst.
May 17, 2030
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
4 sites added, 4 sites removed
Show 4 added (1 Belgium, 1 Germany, 1 New Zealand, 1 South Africa)
  • GSK Investigational Site · Ghent, Belgium
  • GSK Investigational Site · Hanover, Germany
  • GSK Investigational Site · Auckland, New Zealand
  • GSK Investigational Site · Ekurhuleni, South Africa
Show 4 removed
  • GSK Investigational Site · Ghent, Belgium
  • GSK Investigational Site · Hanover, Germany
  • GSK Investigational Site · Papatoetoe Auckland, New Zealand
  • GSK Investigational Site · Reiger Park, South Africa
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    4 sites added, 4 sites removed
    Show 4 added (1 Belgium, 1 Germany, 1 New Zealand, 1 South Africa)
    • GSK Investigational Site · Ghent, Belgium
    • GSK Investigational Site · Hanover, Germany
    • GSK Investigational Site · Auckland, New Zealand
    • GSK Investigational Site · Ekurhuleni, South Africa
    Show 4 removed
    • GSK Investigational Site · Ghent, Belgium
    • GSK Investigational Site · Hanover, Germany
    • GSK Investigational Site · Papatoetoe Auckland, New Zealand
    • GSK Investigational Site · Reiger Park, South Africa
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06537414
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 5, 2024
Start date
Nov 11, 2024
Primary completion
May 31, 2027 (estimated)
Completion
May 17, 2030 (estimated)
Last update
Nov 6, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion